NCT00625573已完成2 期
Phase II Trial of Abraxane and Capecitabine in Metastatic Colon Cancer (COL 01)
Mt. Sinai Medical Center, Miami2 个研究点 分布在 1 个国家目标入组 29 人开始时间: 2007年9月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 29
- 试验地点
- 2
- 主要终点
- To evaluate the efficacy by means of response rate of Abraxane and capecitabine in combination, in the treatment of patients with colorectal cancer in the 2nd or 3rd line metastatic setting following failure of irinotecan or oxaliplatin based therapy
研究概览
简要总结
This is an open-label, phase II study to evaluate the efficacy and safety of Abraxane in combination with Capecitabine in patients with metastatic colorectal cancer in the second or third line
详细描述
Inclusion Criteria
- Signed written informed consent
- Patients with histologically or cytologically confirmed stage IV colorectal cancer who have failed either irinotecan-based, oxaliplatin-based or both. ECOG performance status of 0-2
- Presence of measurable disease by radiographic study (including CT or MRI scan, or chest x-ray) or physical examination
- At least 3 weeks since last major surgery.
- At least 6 weeks since prior radiotherapy providing that the extent and site of radiotherapy fields are such that marked bone marrow suppression is NOT expected. Patients who have received palliative radiotherapy must have recovered from any reversible toxic effects e.g. nausea and vomiting caused by radiation of fields.
- At least 4 weeks since prior chemotherapy.
- Pt with reproductive potential must use effective BC
Required Screening Laboratory Criteria:
- Hemoglobin 9.0g/dL
- WBC 3,500/mm3 [ 3.5 x 109/L]
- Neutrophils 1,500/mm3 [1.5 x 109/L]
- Platelets 100,000/mm3 [ 100.0 x 109/L]
- Creatinine 1.5 mg/dL (133 micromol/L) AND creatinine clearance 60 mL/min • A probable life expectancy of at least 6 months.
Exclusion Criteria
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 90 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed written informed consent
- •Patients with histologically or cytologically confirmed stage IV colorectal cancer who have failed either irinotecan-based, oxaliplatin-based or both. ECOG performance status of 0-2
- •Presence of measurable disease by radiographic study (including CT or MRI scan, or chest x-ray) or physical examination
- •At least 3 weeks since last major surgery.
- •At least 6 weeks since prior radiotherapy providing that the extent and site of radiotherapy fields are such that marked bone marrow suppression is NOT expected. Patients who have received palliative radiotherapy must have recovered from any reversible toxic effects e.g. nausea and vomiting caused by radiation of fields.
- •At least 4 weeks since prior chemotherapy.
- •Pt with reproductive potential must use effective BC
- •Required Screening Laboratory Criteria:
- •Hemoglobin 9.0g/dL
- •WBC 3,500/mm3 [ 3.5 x 109/L]
- •Neutrophils 1,500/mm3 [1.5 x 109/L]
- •Platelets 100,000/mm3 [ 100.0 x 109/L]
- •Creatinine 1.5 mg/dL (133 micromol/L) AND creatinine clearance 60 mL/min
- •A probable life expectancy of at least 6 months
排除标准
- •No brain metastases.
- •If female of childbearing potential, pregnancy test is negative.
- •Concomitant malignancies or previous malignancies other than colorectal cancer within the last five years, with the exception of adequately treated basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, or low grade prostate cancer.
- •Active infection.
- •Concurrent severe medical problems unrelated to the malignancy, which would significantly limit full compliance with the study or expose the patient to extreme risk.
- •Sexually active patients refusing to practice adequate contraception. (condom plus spermicide, or other form of birth control)
- •Patients with conditions which might affect absorption of an oral drug (for example intermittent obstruction) should be excluded unless discussed and agreed with the principal investigator
- •History of grade 3 or 4 toxicity to fluoropyrimidines.
- •Pre-existing neuropathy ≥ NCI CTC grade 2.
结局指标
主要结局
To evaluate the efficacy by means of response rate of Abraxane and capecitabine in combination, in the treatment of patients with colorectal cancer in the 2nd or 3rd line metastatic setting following failure of irinotecan or oxaliplatin based therapy
时间窗: One year
次要结局
- To evaluate overall survival, time to progression, response duration, time to response and safety of this combination(One Year)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
Phase II Study of Abraxane and Gemicitabine in Patients With Advanced Adenocarcinoma Non-Small Cell Lung Cancer Progressing After First-Line Platinum-Based ChemotherapyPatients With Stage IV or Recurrent Adenocarcinoma of the LungNCT02303977Abramson Cancer Center at Penn Medicine37
已完成
2 期
Abraxane and Avastin as Therapy for Patients With Malignant Melanoma, a Phase II StudyMetastatic Malignant MelanomaNCT00462423Lynn E. Spitler, MD50
已完成
2 期
A Phase 2 Feasibility Study of Abraxane and Carboplatin in Epithelial Neoplasms of the UterusEndometrial CancerNCT02744898NYU Langone Health23
已完成
2 期
Carboplatin, Abraxane, and Bevacizumab in Previously Untreated Patients With Advanced Non-Small Cell Lung CancerNon-small Cell Lung CancerNCT00642759Massachusetts General Hospital36
终止
2 期
Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial MetastasesMetastatic Breast Cancer With Intracranial MetastasesNCT01934894SCRI Development Innovations, LLC11